Cover Image

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

Unchalee Permsuwan,1 Piyameth Dilokthornsakul,2 Surasak Saokaew,2–4 Kednapa Thavorn,5–7 Nathorn Chaiyakunapruk2,4,8,9 1Faculty of Pharmacy Chiang Mai University, Chiang Mai, 2Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phit...

Full description

Saved in:

Bibliographic Details
Main Authors:	Permsuwan U (Author), Dilokthornsakul P (Author), Saokaew S (Author), Thavorn K (Author), Chaiyakunapruk N (Author)
Format:	Book
Published:	Dove Medical Press, 2016-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
by: Capuano A, et al.
Published: (2013)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
by: Christina S. Kwon, et al.
Published: (2018)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak, et al.
Published: (2020)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Elisabetta Bigagli, et al.
Published: (2020)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023)

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017)

Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
by: Swarna Bharathi Kalli, et al.
Published: (2022)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021)

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
by: Cheng-Yi Wang, et al.
Published: (2023)

Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
by: Fan YJ, et al.
Published: (2015)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review
by: Xin Jiang, et al.
Published: (2024)

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification
by: Danielle K. Nagy, et al.
Published: (2024)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024)

Urinary exosomal microRNA profiling in type 2 diabetes patients taking dipeptidyl peptidase-4 inhibitor compared with sulfonylurea
by: Nam-Jun Cho, et al.
Published: (2021)

Discovery of Potential Natural Dipeptidyl Peptidase-4 Inhibitors for Type-2 Diabetes Treatment via Structure-Based Virtual Screening
by: Sara Ranjbar, et al.
Published: (2019)

The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from to
by: Shian-Ren Lin, et al.
Published: (2019)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
by: Olesya M. Taylor, PharmD, BCPS, et al.
Published: (2020)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021)

Association of dipeptidyl peptidase-4 inhibitor and recurrent pancreatitis risk among patients with type 2 diabetes: A retrospective cohort study
by: Yi-Sun Yang, et al.
Published: (2024)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022)

Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
by: Seung Hee Choi, et al.
Published: (2017)

Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus
by: Junichi Okada, et al.
Published: (2019)

Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study
by: Shih-Wei Lai, et al.
Published: (2017)

Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Katharina Doni, et al.
Published: (2022)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
by: Yassin SA, et al.
Published: (2017)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021)

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis
by: Dan Liu, et al.
Published: (2019)

In silico studies of Ruellia tuberosa L. compounds as aldose reductase, dipeptidyl peptidase 4, and α-glucosidase inhibitors against type 2 diabetes mellitus
by: Ekowati Retnaningtyas, et al.
Published: (2024)

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects
by: Rhee SJ, et al.
Published: (2016)

Characterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study
by: Alomgir Hossain, et al.
Published: (2024)

Hepatoprotective effect of dipeptidyl peptidase-4 inhibitor sitagliptin against carbon tetrachloride-induced liver fibrosis in mice
by: Ahmed A.N Ahmed, et al.
Published: (2021)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
by: Stephen J Wood, et al.
Published: (2022)